title: The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients.
abstract: One hundred and seventy-eight patients with non metastatic inflammatory breast cancer (IBC) have been treated at the Centre H. Becquerel. Median follow up is 67 months (6-178). Every patient received neoadjuvant chemotherapy (mean number of cycles = 4; range: 2-8), followed by a loco regional treatment (radiotherapy = XRT or modified radical mastectomy = S), followed by adjuvant chemotherapy. During this period, the types of chemotherapy and locoregional treatment have been the following: Study I: 64 patients treated with CMF or AVCF and XRT; Study II: 83 patients, treated with either AVCF, FAC or VAC followed by S (n = 38) or XRT (n = 22) in case of complete or partial response, or followed by XRT (23) in case of initial supraclavicular lymph node involvement or lack of response after chemotherapy; Study III: 31 patients treated with FEC-HD + Estrogenic recruitment followed by S and XRT after adjuvant chemotherapy, except seven patients who received XRT (refusal of surgery). Although objective response rates (= 56.2, 73.5 and 93.5% for study I, II and III respectively) are statistically better in the 3rd study, this does not translate in dramatically different disease free survival (median = 16.7, 19 and 22.2 months respectively for study I, II and III) or overall survival (median = 25, 45.7 and 32.6 months respectively for study I, II and III). Analysis of subset of patients without supra clavicular lymph node involvement where neoadjuvant chemotherapy obtained at least a 50% response reveals a median disease free survival and median overall survival of respectively 38.3 and 60.1 months for patients who underwent S vs 19 and 38.3 months for those who received XRT (P = 0.15). These studies suggest that surgery has no deleterious effect on outcome of IBC. Advantage on disease free survival or overall survival from intensive chemotherapy in IBC remains to be proven with appropriate randomised trials.
authors.affiliation: Service d'Oncologie Médicale, Centre H. Becquerel, Rouen, France.
authors.forename: B
authors.initials: B
authors.lastname: Chevallier
authors.forename: P
authors.initials: P
authors.lastname: Bastit
authors.forename: Y
authors.initials: Y
authors.lastname: Graic
authors.forename: J F
authors.initials: JF
authors.lastname: Menard
authors.forename: J P
authors.initials: JP
authors.lastname: Dauce
authors.forename: J P
authors.initials: JP
authors.lastname: Julien
authors.forename: B
authors.initials: B
authors.lastname: Clavier
authors.forename: A
authors.initials: A
authors.lastname: Kunlin
authors.forename: J
authors.initials: J
authors.lastname: D'Anjou
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002173:Cancer Care Facilities; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012074:Remission Induction; D016019:Survival Analysis